Paul Studenic

Development of digital decision-support tool for healthcare professionals: -Alert clinicians when a patient may have D2TRA -Support personalised treatment based on patient subtype, clinical characteristics & patient preference The tool will be evaluated in a pilot clinical study

Today is Rare Disease Awareness Day! 🤝At #EULAR, we stand with everyone living with rare rheumatic diseases — conditions that are often overlooked, underdiagnosed, and misunderstood. Together, let’s raise awareness to promote earlier diagnosis and better access to care.

STRATA-FIT: Your new hub for D2T-RA insights Exciting update! Our website has been transformed into your ultimate resource for: Latest project news Cutting-edge research on D2T-RA Patient perspectives Clinical insights Upcoming events 👉 Explore now: strata-fit.eu

🚀Join us on the EULAR webinar with Quality of Care: "Quality indicators", explaining how they are developed, implemented, measured, adapted over time, and prioritised, with practical examples. 💻 19 March 2026, 17:00 - 18:00 CET Register here 👉 pulse.ly/cr6uwvdiyj

🔬 The TREAT EARLIER trial investigated which arthralgia patients with subclinical inflammation respond best to a 1-year course of methotrexate treatment. 📊 Only 38% of treated patients achieved MRI-defined response. Responders were identified by higher baseline subclinical inflammation, particularly multiple sites of tenosynovitis (PPV 77–79%). 💡 Results support a precision medicine approach: arthralgia patients with extensive subclinical tenosynovitis/osteitis may benefit most from early methotrexate intervention. 🔗 rmdopen.bmj.com/content/12/1/e…

🔄🩺 Relapse patterns in Granulomatosis with Polyangiitis matter for risk counselling. In 795 patients, organ involvement at diagnosis strongly predicted relapse in the same organ (ENT, lungs, kidneys, eyes, CNS). 🔹 56% relapsed only in initially involved organs 🔹 New organ disease was uncommon and rarely isolated 🔹 Certain baseline features lowered risk of new-organ relapse Useful data to personalise follow-up and patient counselling 🔗rmdopen.bmj.com/content/11/4/e…

STRATA-FIT New Year Wishes 2026: Challenging RA Differently For years, challenging RA cases lacked clear guidance. Our D2T framework is changing that. In 2026, we're setting new standards for understanding and treating complex rheumatoid arthritis.

🧬 Who is really “at risk” of RA among first-degree relatives? In the SCREEN-RA cohort (n=1544 RA- first-degree relatives , mean follow-up 7.1 yrs): ✅ 27 developed RA (1.7%) ✅ 126 developed seropositive inflammatory arthritis (8.2%) Using a balanced random forest model: 🔹 High sensitivity (≥0.82), but modest specificity 🔹 Top predictors of future RA: • Rheumatoid factor • EULAR clinically suspected arthralgia symptoms • Multiple affected family members 🔹 For seropositive IA, age, gender and anti-RA33 autoantibodies were most important 🔓 rmdopen.bmj.com/content/11/4/e…

@STRATA_FIT The upcoming year will be exciting - Putting ideas in Action on the federated platform 😀

Our team is making significant strides in #D2TRA research. Data extraction is progressing across 6 centers, w/ harmonized datasets installed in 5 sites. Initial analyses reveal consistent patterns in #D2TRA distribution, bringing us closer to understanding this complex condition.

The development and validation of a EULAR disease activity score in #Antiphospholipid syndrome. Honored to chair this EULAR Task Force with the contribution of an international group of #APS experts/Collaborators, patients with APS, and HPRs. sciencedirect.com/science/articl…

🌟Are you living with a rheumatic and musculoskeletal disease and want to bring the patients’ perspective in rheumatology research? Join the 4th EULAR Online Course for Patient Research Partners! 📅Learn more and register before 30 November 2025 here👉pulse.ly/mkqri5mk2e

Considering patient goals, lifestyle & lived experiences. Supporting clinicians in making complex treatment decisions. Individualized care is not just a goal. Let’s learn, share, & build a more inclusive world! bit.ly/4q11Ukg #RMDreams #WAD2025 #WorldArthritisDay #EULAR

Die @oegrr erweitert ihre Kommunikationsbandbreite! #Podcasts zu einer Vielfalt von #Rheuma Themen werden für alle Interessierte über den Herbst hinweg gelaunched werden instagram.com/stories/oegrr/…

🚀Join EULAR webinar with QoC: "Points to consider when considering starting targeted therapies in patients with inflammatory arthritis and a recent history of cancer" 🖥️Thursday, 16 October 2025, 18:00 - 19:00 CEST Register here 👉pulse.ly/chyao8weqk #Rheumatology #QoC

📰NEWS ALERT! EULAR & ERS have developed new clinical practice guidelines for interstitial lung disease (ILD) in connective tissue diseases (CTD). 📖Read the full #eularPressRelease here: pulse.ly/ekwjw5wrq3 #Rheumatology #Pulmonology #ILD #CTD

📢 It´s Still's Disease Awareness Day! Still's Disease, a rare and challenging form of arthritis that affects both children and adults. By spreading knowledge and supporting research, we can improve diagnosis, and care. #eularADVOCACY #EULAR

🚨 Hot, ahead of press ‼️: Plenary session Josef Smolen presents the 2025 Recommendations update for Management of RA at #APLAR25 How similar/different will they be ? @RheumNow

📢Strengthen your National PARE Organisation with EULAR's Engagement Programme! 🌟Request a EULAR representative to boost your impact at events. 📌Requests need to be submitted 4-6 months in advance 💡Learn more 👉 pulse.ly/wox7xf7rpj #EULAR #eularPARE #youngPARE

On #WorldSjögrensDay let’s celebrate its recognition as a DISEASE with the nomenclature change, and let’s raise awareness aiming to address all the unmet needs in the near future 🙌 nature.com/articles/s4158…